Susquehanna International Group, LLP Merus N.V. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$47.19 - $58.84 $1.65 Million - $2.06 Million	-35,000 Reduced 43.91%	44,700 $2.23 Million
Q2 2024 Aug 15, 2024	BUY	$39.81 - $60.2 $1.51 Million - $2.29 Million	38,000 Added 91.13%	79,700 $4.72 Million
Q1 2024 May 07, 2024	BUY	$28.03 - $51.82 $936,202 - $1.73 Million	33,400 Added 402.41%	41,700 $1.88 Million
Q4 2023 Feb 14, 2024	SELL	$20.06 - $28.66 $308,924 - $441,364	-15,400 Reduced 64.98%	8,300 $228,000
Q3 2023 Nov 14, 2023	SELL	$20.13 - $27.29 $42,273 - $57,309	-2,100 Reduced 8.14%	23,700 $558,000
Q2 2023 Aug 11, 2023	BUY	$18.33 - $27.18 $273,117 - $404,982	14,900 Added 136.7%	25,800 $679,000
Q1 2023 May 16, 2023	SELL	$14.25 - $20.5 $39,900 - $57,400	-2,800 Reduced 20.44%	10,900 $200,000
Q4 2022 Feb 14, 2023	BUY	$12.8 - $23.66 $175,360 - $324,142	13,700 New	13,700 $211,000
Q1 2022 May 16, 2022	SELL	$23.58 - $30.91 $792,288 - $1.04 Million	-33,600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $672,000 - $1.08 Million	33,600 New	33,600 $1.07 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.